CIK 0001621227 · Non-accelerated filer<br>Smaller reporting company
Adaptimmune Therapeutics PLC
Sign in to watch- Ticker
- ADAPY
- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- United Kingdom
- Entity type
- operating
- Phone
- 44 1235 430000
- Business address
- 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE, United Kingdom
- Former names
- Adaptimmune Ltd
- 4 Open-market sale Chief Medical Officer sold 2,111 shares at $5.67 ($11,968)
- 4 Open-market sale Chief Patient Supply Officer sold 4,358 shares at $5.67 ($24,708)
- 4 Open-market sale Chief Executive Officer sold 9,879 shares at $5.67 ($56,009)
- 4 Open-market sale Chief Operating Officer sold 2,234 shares at $6.15 ($13,744)
- 4 Open-market sale Chief Patient Supply Officer sold 1,058 shares at $6.15 ($6,509)
- 4 Open-market sale Chief Medical Officer sold 841 shares at $6.15 ($5,174)
- 4 Open-market sale Chief Executive Officer sold 2,707 shares at $6.15 ($16,654)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Chief Patient Supply Officer sold 1,065 shares at $5.33 ($5,674)
- 4 Open-market sale Chief Operating Officer sold 3,499 shares at $5.33 ($18,642)
- 4 Open-market sale Chief Medical Officer sold 845 shares at $5.33 ($4,502)
- 4 Open-market sale Chief Executive Officer sold 4,967 shares at $5.33 ($26,464)
- 4 Open-market buy Chief Financial Officer bought 24,000 shares at $0.69 ($16,550)
- 4 Open-market buy Chief Operating Officer bought 207,000 shares at $0.69 ($143,824)
- 4 Open-market sale Chief Executive Officer sold 2,776 shares at $8.51 ($23,637)
Page 8 of 18 · 351 filings